ATR and small cell lung carcinoma: Moreover, in SLFN11-low SCLC cell lines that are resistant to lurbinectedin, the addition of ceralasertib, an ATR inhibitor, resensitized resistant cells, providing a rationale for combining lurbinectedin with ATR inhibitors to overcome resistance in SCLC with low SLFN11 expression.